BMEA - NASDAQ
Biomea Fusion, Inc.
$1.38
+6.2%Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotBiomea Fusion, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Biomea Fusion, Inc. Cash Flow Statement
BMEA • NASDAQ
| Biomea Fusion, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-61.8M | -138.4M | -117.3M | -81.8M | -41.6M | -5.3M | -1.2M | |
1.4M | 0.0 | 1.5M | 691K | 953K | 132K | 0.0 | |
9.5M | 19.1M | 14.1M | 10.3M | 0.0 | 0.0 | 0.0 | |
-15.8M | 4.6M | 2.7M | 715K | 6.8M | 322K | 98K | |
-3.7M | -5.1M | 2.3M | 7.7M | -1.6M | 411K | -81K | |
-70.4M | -119.9M | -96.6M | -62.4M | -35.4M | -4.5M | -1.3M | |
INVESTING ACTIVITIES | |||||||
(0.0) | -362K | -3.4M | -1M | -3.2M | -51K | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -38.5M | (0.0) | (0.0) | |
0.0 | 0.0 | 1.2M | 28.4M | 8.3M | 0.0 | 0.0 | |
(0.0) | -362K | -2.2M | (27.3M) | -33.4M | -51K | (0.0) | |
FINANCING ACTIVITIES | |||||||
67.9M | 1.7M | 161.8M | 0.0 | 153.2M | 65.9M | 1.4M | |
0.0 | 0.0 | 0.0 | 0.0 | -36K | 36K | 0.0 | |
0.0 | 0.0 | 2M | 1.2M | 0.0 | 0.0 | 0.0 | |
67.9M | 1.7M | 163.8M | 1.2M | 153.2M | 66M | 1.4M | |
CASH FLOW SUMMARY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | -351K | 1.0 | 0.0 | |
-2.5M | -118.6M | 65M | -33.8M | 84M | 61.5M | 161K | |
58.6M | 177.2M | 112.3M | 146.1M | 61.7M | 239K | 78K | |
56.2M | 58.6M | 177.2M | 112.3M | 145.7M | 61.7M | 239K | |
-70.4M | -120.3M | -100M | -63.4M | -38.6M | -4.5M | -1.3M |
SEC Filings
BMEA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 14, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Related Guides
Continue your BMEA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.